Morepen Laboratories · NSE: MOREPENLAB · BSE: 500288
Q3 FY20 results · Oct–Dec 2019
Morepen Laboratories reported revenue from operations of ₹230.06 crore (up 8.4% from Q3 FY19) and net profit of ₹10.82 crore (up 21.3% from Q3 FY19) for Q3 FY20 (Oct–Dec 2019), on a consolidated basis.
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 230.06 | 212.16 | +8.4% | 213.43 | +7.8% |
| Other income | 4.60 | 2.43 | +89.1% | 2.81 | +63.6% |
| Total income | 234.66 | 214.59 | +9.4% | 216.24 | +8.5% |
| Profit before share of associates & JVs and tax | 10.83 | 9.04 | +19.8% | 9.24 | +17.2% |
| Share of profit/(loss) of associates & JVs | 0.00 | 0.01 | 0.00 | ||
| Net profit for the period | 10.82 | 8.92 | +21.3% | 3.71 | +191.4% |
| EPS, basic (₹) | 0.24 | 0.20 | +20.0% | 0.09 | +166.7% |
| Net margin (%) | 4.7 | 4.2 | 1.7 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 213.49 | 198.32 | +7.6% | 199.88 | +6.8% |
| Other income | 4.60 | 2.43 | +89.1% | 2.81 | +63.7% |
| Total income | 218.09 | 200.76 | +8.6% | 202.70 | +7.6% |
| Profit before tax | 9.91 | 9.74 | +1.7% | 9.69 | +2.2% |
| Net profit for the period | 9.91 | 9.74 | +1.7% | 4.17 | +137.6% |
| EPS, basic (₹) | 0.22 | 0.22 | +0.0% | 0.10 | +120.0% |
| Net margin (%) | 4.6 | 4.9 | 2.1 |
Consolidated
- Filed with BSE
- 18 Feb 2020, 15:01 IST
- Board meeting
- 14 Feb 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 18 Feb 2020, 15:01 IST
- Board meeting
- 14 Feb 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE